For reprint rights or to purchase a copy of your Daily Journal photo, email jeremy@reprintpros.com for prices or call 949-702-5390.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Corporate

Jul. 27, 2013

Conatus, AcelRx strengthen biotech IPO trend

Two initial public offerings in California this week extend the trend of biotech and pharmaceutical companies reaching out to the public markets amid dwindling investment from private sources.


By Dominic Fracassa


Daily Journal Staff Writer


After facing several years of dwindling capital investments from private sources, biotech and life sciences companies have been launching into the public capital markets this year with a vengeance.


Another example of that came Thursday, when Conatus Pharmaceuticals Inc. made its debut on the Nasdaq with the help of legal counsel from Latham & Watkins LLP. The San Diego-based biotechnology comp...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.